First Mercantile Trust Co. raised its stake in Retrophin Inc. (NASDAQ:RTRX) by 35.4% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 5,930 shares of the biopharmaceutical company’s stock after buying an additional 1,550 shares during the period. First Mercantile Trust Co.’s holdings in Retrophin were worth $106,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the company. Alambic Investment Management L.P. raised its position in Retrophin by 9.0% in the second quarter. Alambic Investment Management L.P. now owns 18,800 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 1,550 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Retrophin by 71.1% in the second quarter. UBS Asset Management Americas Inc. now owns 19,500 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 8,100 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Retrophin by 30.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 20,300 shares of the biopharmaceutical company’s stock worth $364,000 after buying an additional 4,700 shares during the last quarter. Bank of Montreal Can bought a new position in shares of Retrophin during the second quarter worth $368,000. Finally, Nationwide Fund Advisors raised its position in shares of Retrophin by 3.8% in the second quarter. Nationwide Fund Advisors now owns 23,344 shares of the biopharmaceutical company’s stock worth $416,000 after buying an additional 862 shares during the last quarter.
Shares of Retrophin Inc. (NASDAQ:RTRX) opened at 22.67 on Friday. The stock has a 50 day moving average of $20.55 and a 200-day moving average of $17.58. The company has a market cap of $832.69 million, a price-to-earnings ratio of 9.21 and a beta of 1.02. Retrophin Inc. has a 12 month low of $11.60 and a 12 month high of $24.57.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.30. Retrophin had a negative return on equity of 0.52% and a net margin of 83.57%. The company earned $33.30 million during the quarter, compared to the consensus estimate of $32.73 million. The company’s quarterly revenue was up 38.2% compared to the same quarter last year. On average, analysts forecast that Retrophin Inc. will post $0.09 EPS for the current year.
A number of research analysts have weighed in on the stock. JMP Securities reaffirmed a “buy” rating on shares of Retrophin in a research note on Saturday, July 9th. Zacks Investment Research lowered shares of Retrophin from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Leerink Swann reaffirmed a “buy” rating and issued a $27.00 price target on shares of Retrophin in a research note on Monday, June 27th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $28.00 price target (up previously from $25.00) on shares of Retrophin in a research note on Monday, August 8th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Retrophin currently has an average rating of “Buy” and a consensus price target of $27.60.
In other Retrophin news, EVP Alvin Shih sold 8,750 shares of the stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $16.24, for a total transaction of $142,100.00. Following the completion of the sale, the executive vice president now owns 158,334 shares of the company’s stock, valued at approximately $2,571,344.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.41% of the company’s stock.
Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc. (NASDAQ:RTRX).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.